VP01- mechanistic phase II study in systemic sclerosis

The study was a mechanistic study designed to investigate the effect of C21 on cold-induced vasoconstriction in patients with Raynaud’s phenomenon secondary to systemic sclerosis (SSc). The aim of the study was to shed light on the AT2 receptor’s role in improving blood flow in diseased tissues, an effect that may benefit patients with SSc-related pulmonary fibrosis as well as patients with IPF.

Twelve patients with SSc had both hands subjected to a challenge with cold water and the recovery periods on drug or on placebo were compared. The study concluded that patients on C21 showed a statistically significant (p.0.04) evidence of restored skin temperature as a measure of dilated peripheral resistance vessels, 15 minutes after the cold challenge. This vasodilatory effect of C21 is believed to be beneficial in fibrotic diseases such as IPF.

Read more about the study at clinicaltrials.gov

https://vicorepharma.com/wp-content/uploads/2021/01/ssc-study-design.png SSc study design